Management of immune-mediated thrombocytopenia
Nenhuma Miniatura disponível
Citações na Scopus
0
Tipo de produção
bookPart
Data de publicação
2022
Título da Revista
ISSN da Revista
Título do Volume
Editora
WILEY
Autores
Citação
Gabe, C.; Arnold, D. M.; Smith, J. W.; Warkentin, T. E.. Management of immune-mediated thrombocytopenia. In: . Rossi's Principles of Transfusion Medicine: WILEY, 2022. p.402-423.
Resumo
Low circulating platelet numbers can be caused by platelet underproduction, sequestration, hemodilution, consumption, or destruction. This chapter explores the problem of immune-mediated thrombocytopenia, including autoimmune conditions, secondary immune conditions, and alloimmune conditions. Platelets are usually quantitated during a complete blood cell count with a particle counter. Various monoclonal antibody-based assays can be used to detect plate let antibodies. The principal mechanism for immune-mediated thrombocytopenia is antibody-mediated destruction of platelets. Drugs can produce several immune-mediated thrombocytopenic disorders. Heparin-induced thrombocytopenia is a clinicopathologic syndrome, that is, the diagnosis is made most reliably on both clinical and serologic grounds. Alloantigens are genetically determined molecular variations of proteins or carbohydrates that can be recognized immunologically by some healthy persons. Platelet transfusion refractoriness, which is failure to achieve the expected platelet increment after two consecutive platelet transfusion episodes, has several explanations. © 2022 John Wiley & Sons Ltd.
Palavras-chave
Alloantigens, Heparin-induced thrombocytopenia, Immune-mediated thrombocytopenia, Monoclonal antibody-based assays, Platelet transfusion refractoriness
Referências
- Warkentin T., Drug-induced immune-mediated thrombocytopenia-from purpura to thrombosis, NEngl J Med, 356, 9, pp. 891-893, (2007)
- Provan D., Arnold D.M., Bussel J.B., Et al., Updated international consensus report on the investigation and management of primary immune thrombocytopenia, Blood Adv, 3, 22, pp. 3780-3817, (2019)
- Vrbensky J.R., Moore J.E., Arnold D.M., Et al., The sensitivity and specificity of platelet autoantibody testing in immune thrombocytopenia: A systematic review and meta-analysis of a diagnostic test, J Thromb Haemost, 17, 5, pp. 787-794, (2019)
- Arnold D.M., Kukaswadia S., Nazi I., Et al., A systematic evaluation of laboratory testing for drug-induced immune thrombocytopenia, J Thromb Haemost, 11, 1, pp. 169-176, (2013)
- Greinacher A., Selleng K., Warkentin T.E., Autoimmune heparin-induced thrombocytopenia, J Thromb Haemost, 15, 11, pp. 2099-2114, (2017)
- Warkentin T.E., High-dose intravenous immunoglobulin for the treatment and prevention of heparin-induced thrombocytopenia: A review, Exp Rev Hematol, 12, 8, pp. 685-698, (2019)
- Bouguignon A., Arnold D.M., Warkentin T.E., Et al., Adjunct immune globulin for vaccine-induced thrombotic thrombocytopenia, N Engl J Med, 385, 8, pp. 720-728, (2021)
- Huynh A., Kelton J.G., Arnold D.M., Et al., Antibody epitopes in vaccine-induced immune thrombotic thrombocytopaenia, Nature, 596, 7873, pp. 565-569, (2021)
- Warkentin T.E., Smith J.W., The alloimmune thrombocytopenic syndromes, Transfus Med Rev, 11, 4, pp. 296-307, (1997)
- Petermann R., Bakchoul T., Curtis B.R., Et al., Investigations for fetal and neonatal alloimmune thrombocytopenia: Communication from the SSC of the iSTH. Subcommitee on Platelet Immunology, J Thromb Haemost, 16, 12, pp. 2526-2529, (2018)